# VOLT CE Mark Study

Study · id `cardio:ct-nct06106594` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06106594](<https://clinicaltrials.gov/study/NCT06106594>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06106594

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06106594. Allocation not applicable; no masking; primary purpose treatment. Start 2023-10-24 (actual); primary completion 2027-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06106594, source copy `cardio:ctgov-nct06106594-2026-10-30`, retrieved 2026-10-31)
- Started: 2023-10-24 (actual) (ClinicalTrials.gov record NCT06106594, source copy `cardio:ctgov-nct06106594-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT06106594, source copy `cardio:ctgov-nct06106594-2026-10-30`, retrieved 2026-10-31)
- Completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT06106594, source copy `cardio:ctgov-nct06106594-2026-10-30`, retrieved 2026-10-31)
- Countries: Australia; Austria; Belgium; Czechia; Germany; Netherlands; Spain (ClinicalTrials.gov record NCT06106594, source copy `cardio:ctgov-nct06106594-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06106594-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: VOLT CE Mark Study
- Condition: Atrial Arrhythmia
- Condition: Atrial Fibrillation
- Condition: Paroxysmal Atrial Fibrillation
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): Pulsed Field Ablation
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: ea941d6677c38444c9433eab7da731a8ffd4968347b79110c5937387a2c1df33
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
